Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S. Wang, Amir T. Fathi, Stephane DeBotton et al.|The Lancet Oncology|2024Cited by 106
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid LeukemiaHarry P. Erba, Eunice S. Wang, Amir T. Fathi et al.|Blood|2022Cited by 71
Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AMLJordi Esteve Reyner, Pau Montesinos, James M. Foran et al.|Journal of Clinical Oncology|2025Cited by 33